VIDAZA® Treatment for MDSa

Initiating Treatment at Time of Diagnosis

The earlier VIDAZA® is started, the earlier disease modification can start.

VIDAZA® has to be incorporated into the DNA of BM replicating cells. It takes time to:

  • control the proliferation of the malignant clone
  • reactivate the normal differentiation processes in the non-compromised precursor lineages of final blood cells1

Initiating VIDAZA® treatment at the time of diagnosis can help produce the following benefits:

VIDAZA® (AZACITIDINE) incorporation into DNA requires actively dividing cells

Initiating VIDAZA® treatment at the time of diagnosis delays time to AML progression1

The risk of AML progression in the first 6 months after diagnosis is reduced 8-fold with VIDAZA® vs. supportive care.2

Patients with AML-Progression (%)

  1. VIDAZA® Summary of Product Characteristics, 2011.
  2. Silverman LR et al. J Clin Oncol. 2002. 20:2429-40.

When initiating VIDAZA® treatment at the time of diagnosis, Int2/HR MDS patients live longer.

Treatment with VIDAZA® significantly increases overall survival in patients with intermediate-2 and high-risk MDS compared with Conventional Care Regimens (CCR*).1

Overall Survival

*Conventional Care Regimen (Best Supportive Care (BSC) only, n=105; Low Dose Ara-C (LDAC, 20 mg/m2/d x 14 d q28-42 d), n=49; Std Chemo (7 + 3), n=25)

  1. Fenaux P et al. Lancet Oncol. 2009. 10:223 – 232.

The lower the transfusion burden at initiation of VIDAZA®, the higher the chances of achieving transfusion independence.1

RBC Transfusions at Baseline

Marked improvement in OS with VIDAZA® is associated with achieving transfusion independence1

  • Median overall survival improved 3-fold for patients who achieved RBC transfusion independence with VIDAZA®, regardless of RBC transfusion burden at baseline, vs patients who remained transfusion dependent (p<0.0001)
  • Overall survival at 2 years for patients who achieved RBC transfusion independence with VIDAZA® was 60-75% greater than overall survival at 2 years in patients who remained transfusion dependent
  • Of patients with the highest RBC transfusion needs at baseline, 73% who achieved transfusion independence were alive after 2 years vs 12% who remained transfusion dependent
  1. Seymour JF et al. ASH, Orlando, 2010. Abstract 1856.
  1. Silverman et al. Cancer. 2011. 117:2697-702.
a. MDS-specific Indication

VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:

  • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
  • chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
b. AML-specific Indication:

Treatment of adult AML patients who are not eligible for haematopoietic stem cell transplantation with 20-30% blasts and multi-lineage dysplasia, according to the WHO classification. WHO classifies RAEB-T patients with blasts ?20% to <30% as AML patients.


This is an international website for VIDAZA® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

The information on this website is based on the European Summary of Product Characteristics (SmPC). Please refer to your country-specific website, or contact a Celgene representative in your country for the latest information specific to your country.